Dr. Reddy’s Labs reported a 15% decline in Q2 net profit, despite a 17% rise in revenue driven by global generics. While analysts acknowledge the strong revenue momentum, opinions are divided on the stock’s future prospects, with ratings ranging from ‘Buy’ to ‘Sell’.
Trump win may boost market in short-term but will bring long-term volatility: Punita Kumar Sinha
I think geopolitics, the landscape could change rapidly. There could be escalations in certain countries, by certain countries. So, I do expect some volatility until
November 6, 2024